Goldman Sachs Maintains Neutral on Bicara Therapeutics, Raises Price Target to $18
Benzinga Newsdesk 5 months ago
NewsPrice TargetAnalyst Ratings
Goldman Sachs analyst Richard Law maintains Bicara Therapeutics (NASDAQ:BCAX) with a Neutral and raises the price target from $16 to $18.
Goldman Sachs analyst Richard Law maintains Bicara Therapeutics (NASDAQ:BCAX) with a Neutral and raises the price target from $16 to $18.